Diamics, Inc., a San Francisco Bay-area medical device and diagnostics company, announced it has appointed Christine A. Meda as President.

"We are pleased to have Christine Meda join our team at this exciting time for our company," said Peter Gombrich, CEO, Diamics, Inc. "Her in-depth industry experience and insight-particularly concerning women's health issues-will help us to accelerate the development of our molecular-based cancer screening and diagnostic systems."

Meda takes over the position from Gombrich, who has been serving in dual capacities as both President and CEO. He will continue as the company's CEO and Chairman of the Board.


Meda comes to Diamics, Inc. from Roche Molecular Systems, a division of Hoffman-LaRoche, where she served as VP of Business Development and VP of the Women's Health portfolio. In this latter capacity, she directed the launches of real-time PCR diagnostic products for Chlamydia, Human Papillomavirus (HPV), Herpes Simplex virus and Strep B.

Previously Meda served as Senior Director of the CNS portfolio at Schering AG pharmaceuticals, where she oversaw life cycle and marketing activities for Betaseron, a multiple sclerosis treatment, and as Medical Affairs Director, responsible for clinical trials for their hematological oncology drugs: Fludara, CamPath and Leukine.

She also held executive positions at Bio-Rad Laboratories, Meridian Diagnostics, and Diagnostic Products Corporation.

Meda earned a B.S. degree from State University of New York, Potsdam Campus, and has completed numerous executive development programs at Diagnostic Products, Schering AG and Roche.

More Voices